Stock Events

Stock Events

CureVac N.V. 

$4.66
485
-$0.01-0.21% Monday 20:59

Statistics

Day High
4.67
Day Low
4.57
52W High
5.72
52W Low
2.48
Volume
1,131,110
Avg. Volume
1,237,990
Mkt Cap
0
P/E Ratio
5.34
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29AprExpected
Q1 2024
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Next
-0.34
0.33
1.01
1.68
Expected EPS
-0.1057059
Actual EPS
N/A

Financials

31.78%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
593.99MRevenue
188.77MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CVAC. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech SE is a direct competitor in the mRNA technology space, focusing on developing vaccines and therapeutics, similar to CureVac's core business.
Moderna
MRNA
Mkt Cap10.61B
Moderna, Inc. is a leader in mRNA therapeutics and vaccines, directly competing with CureVac in the COVID-19 vaccine market and other therapeutic areas.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc., in collaboration with BioNTech, competes in the mRNA vaccine market, particularly with their COVID-19 vaccine, which is in direct competition with CureVac's development.
Novavax
NVAX
Mkt Cap1.36B
Novavax, Inc. competes in the vaccine space, particularly with its protein-based COVID-19 vaccine, offering an alternative to mRNA vaccines like those developed by CureVac.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson competes in the vaccine market with its viral vector COVID-19 vaccine, offering an alternative approach to CureVac's mRNA technology.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC competes with its viral vector COVID-19 vaccine, which is a different technology but serves the same market as CureVac's vaccine candidates.
Sanofi
SNY
Mkt Cap124.45B
Sanofi competes in the vaccine and therapeutic market, working on mRNA vaccines and other technologies that could compete with CureVac's products.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline plc competes in the vaccine space, including collaborations on COVID-19 vaccines and other therapeutic areas that overlap with CureVac's interests.
Arcturus Therapeutics
ARCT
Mkt Cap270.73M
Arcturus Therapeutics Holdings Inc. is involved in the development of mRNA vaccines and therapeutics, making it a direct competitor in the same technology space as CureVac.
Telesis Bio
TBIO
Mkt Cap21,310
Translate Bio, now a part of Sanofi, focuses on mRNA technologies for vaccines and therapeutics, directly competing with CureVac in the mRNA space.

About

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Show more...
CEO
Dr. Alexander Zehnder M.B.A., M.D.
Employees
825
Country
NL
ISIN
NL0015436031

Listings

MX
MX
CVACN.MX
XNAS
US
CVAC

0 Comments

Share your thoughts

FAQ

What is CureVac N.V. stock price today?▼
The current price of CVAC is $4.66 USD — it has decreased by -0.21% in the past 24 hours. Watch CureVac N.V. stock price performance more closely on the chart.
What is CureVac N.V. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange CureVac N.V. stocks are traded under the ticker CVAC.
Is CureVac N.V. stock price growing?▼
CVAC stock has risen by +0% compared to the previous week, the month change is a -0.21% fall, over the last year CureVac N.V. has showed a +22.96% increase.
When is the next CureVac N.V. earnings date?▼
CureVac N.V. is going to release the next earnings report on April 29, 2026.
What were CureVac N.V. earnings last quarter?▼
CVAC earnings for the last quarter are -0.08 USD per share, whereas the estimation was -0.08 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is CureVac N.V. revenue for the last year?▼
CureVac N.V. revenue for the last year amounts to 593.99M USD.
What is CureVac N.V. net income for the last year?▼
CVAC net income for the last year is 188.77M USD.
How many employees does CureVac N.V. have?▼
As of February 02, 2026, the company has 825 employees.
In which sector is CureVac N.V. located?▼
CureVac N.V. operates in the Health Care sector.
When did CureVac N.V. complete a stock split?▼
CureVac N.V. has not had any recent stock splits.
Where is CureVac N.V. headquartered?▼
CureVac N.V. is headquartered in Tübingen, NL.